Summarizing, one can state that the analysis of TFF1 in the AH of RB patients opens the field for additional diagnostic approaches and therapy monitoring, using TFF1 as a potential biomarker for RB tumor cells. This evidence concerns the gene TFF1 and retinoblastoma.